Comparative Effectiveness of Dapagliflozin and Empagliflozin in Type 2 Diabetes
Recent research comparing dapagliflozin and empagliflozin in patients with type 2 diabetes (T2D) found no significant differences in primary cardiorenal outcomes or safety profiles when analyzed across the full study population. The study, published in Diabetes Research and Clinical Practice, conducted a target trial emulation using electronic health records from January 2016 to August 2023, identifying 2,649 new users of dapagliflozin and 2,046 of empagliflozin. After applying inverse probability of treatment weighting (IPTW) for confounding adjustment, 1,662 patients remained in each group for analysis.
The primary composite outcome—sustained eGFR decline ≥30%, end-stage renal disease, heart failure hospitalization, or all-cause mortality—showed no statistically significant difference between the two sodium-glucose cotransporter-2 inhibitors (SGLT2is). Secondary outcomes and safety events, including acute kidney injury, hypoglycemia, urinary tract infection, and fracture, also demonstrated no significant variation between treatment groups.
However, a subgroup analysis revealed an important nuance: among patients without stable prior use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), empagliflozin was associated with a higher risk of all-cause mortality compared to dapagliflozin. This finding suggests that the stability of baseline renin-angiotensin-aldosterone system (RAAS) inhibitor therapy may influence the comparative safety and effectiveness of SGLT2 inhibitors in real-world settings.
Prescribing patterns also varied significantly across medical specialties, highlighting differences in how endocrinologists, cardiologists, and primary care physicians initiate SGLT2 inhibitor therapy. These variations underscore the importance of multidisciplinary collaboration in optimizing T2D management, particularly given that cardiovascular disease remains the leading cause of morbidity and mortality in this population.
The researchers concluded that while dapagliflozin and empagliflozin demonstrate comparable overall effectiveness and safety in T2D, clinical decisions should consider individual patient factors, including prior ACEI/ARB use stability. They emphasized the need for individualized treatment approaches and coordinated care involving cardiology, endocrinology, and primary care to maximize the cardiorenal benefits of SGLT2 inhibitor therapy.
These results align with broader guidance from cardiovascular and diabetes organizations advocating for risk-stratified use of SGLT2 inhibitors based on comorbid conditions and concomitant medications. As real-world evidence continues to evolve, such studies provide critical insights for refining prescribing practices and improving long-term outcomes in diverse patient populations with T2D.